Shamburg News · 8-K filed Nov 16, 2026, 4:52 PM EST

Cue Biopharma Reports Third Quarter 2026 Financial Results and CUE-221 Phase 2 CSU Findings

CUE · Cue Biopharma, Inc.

  • Earnings
  • Materiality: high

Cue Biopharma, Inc. reported third quarter 2026 results, with collaboration revenue of $132 thousand and a net loss of $50.0 million, or $4.74 per share, compared with revenue of $2.1 million and a net loss of $7.4 million in the third quarter of 2025. The company reported $57.9 million in cash and cash equivalents as of September 30, 2026, and highlighted Phase 2 CSU findings for CUE-221 and first-in-human dosing of CUE-401. The filing also disclosed that the ImmunoScape payment right was increased to $5.5 million in November 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-463741.

Written from the filing by Shamburg Markets. Figures are as reported by the company.